Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumors
The assay demonstrates high analytical validity for small variants at VAF > 0.5% and yields actionable biomarkers in a substantial proportion of cases. However, inconsistent clinical documentation and poor integration into care workflows limit the assessment of its clinical impact. We recommend that the implementation of ctDNA-based CGP in public health settings be accompanied by standardized requisition protocols and mandatory clinical data capture.
Authors
- Leonhard Müllauer (ORCID: https://orcid.org/0000-0002-3399-078X)
- Ana‐Iris Schiefer (ORCID: https://orcid.org/0000-0003-3555-8672)
- Éva Compérat (ORCID: https://orcid.org/0000-0001-8488-543X)
- Felicitas Oberndorfer
- Lucia Zisser (ORCID: https://orcid.org/0000-0001-9454-2860)
- Lawrence M. Schopfer (ORCID: https://orcid.org/0000-0002-1785-9247)
- André Oszwald (ORCID: https://orcid.org/0000-0002-8298-6381)
Institutions
- Medical University of Vienna (AT)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1186/s12885-025-15354-8
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00